Candel Therapeutics Secures $15 Million to Enhance Cancer Solutions
Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ: CADL), a clinical-stage biopharmaceutical company dedicated to creating advanced multimodal immunotherapies for cancer treatment, has entered into an agreement to sell approximately 3.2 million shares of common stock. This registered direct offering is priced at $4.67 per share, aiming to raise approximately $15 million in gross proceeds, subject to customary closing conditions.
The buyers participating in this offering include existing healthcare-focused institutional investors, as well as executive officers and board members of Candel. This endeavor demonstrates a strong belief in the Company's strategic direction and its potential for transformative cancer therapies.
Paul Peter Tak, M.D., Ph.D., and President and CEO of Candel, expressed satisfaction regarding the enhanced financial position resulting from this offering. He stated, “These resources are intended to bolster pre-commercialization efforts and launch readiness for CAN-2409 in prostate cancer, pending regulatory approval. The support from investors underscores confidence in our innovative strategies to tackle complex tumors.”
The funds raised will be allocated to crucial activities related to launch preparation and medical affairs, particularly to advance the Biologics License Application (BLA) for CAN-2409 in prostate cancer, anticipated to be submitted by the end of 2026, as well as for other general corporate purposes.
The common stock shares are being made available through a shelf registration statement previously filed with the U.S. Securities and Exchange Commission (SEC). This offering will be executed by means of written prospectus and prospectus supplement that forms part of the registration statement. A detailed prospectus supplement containing additional information about the offering will be filed with the SEC and accessible on the SEC’s website.
For Candel Therapeutics, the journey towards enhanced cancer treatment continues. The company focuses on breakthrough immunotherapy solutions that are not only individualized but also robust in combating cancer.
About Candel Therapeutics
Candel Therapeutics specializes in developing off-the-shelf biological immunotherapies designed to elicit tailored, systemic anti-tumor immune responses. Their leading candidate, CAN-2409, comes from a novel adenovirus platform, which has demonstrated significant potential in various clinical trials.
The company recently completed impressive phase 2a trials for CAN-2409 targeting non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). It has also conducted a pivotal phase 3 trial for localized prostate cancer under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration (FDA). CAN-2409 has garnered fast-track designation from the FDA for treating PDAC and stage III/IV NSCLC, particularly in patients resistant to first-line therapies.
Another promising candidate, CAN-3110 from the herpes simplex virus (HSV) platform, is currently being tested in an ongoing phase 1b trial for recurrent high-grade glioma (rHGG). Initial findings from this study have shown promise, with CAN-3110 receiving both Fast Track and Orphan Drug designations from the FDA.
Utilizing the enLIGHTEN™ Discovery Platform, Candel is paving the way for innovative viral immunotherapies aimed at solid tumors. This systematic approach integrates advanced analytics with human biology to enhance their therapeutic arsenal.
For more information about Candel Therapeutics, interested parties can visit their official site at www.candeltx.com.
Frequently Asked Questions
What is the main purpose of the $15 million offering?
The funds raised will support critical pre-commercialization activities for CAN-2409 in prostate cancer and general corporate purposes.
Who are the primary investors in this offering?
Investors include existing healthcare-focused institutional investors, executive officers, and board members of Candel Therapeutics.
What is CAN-2409 and its significance?
CAN-2409 is a leading cancer treatment candidate aimed at stimulating individualized immune responses to combat tumors, currently in advanced clinical trials.
What clinical trials has CAN-2409 completed?
CAN-2409 has undergone successful phase 2a trials for NSCLC and PDAC and a pivotal phase 3 trial for localized prostate cancer.
What designations has CAN-2409 received from the FDA?
CAN-2409 has received Fast Track Designation, Regenerative Medicine Advanced Therapy (RMAT) Designation, and Orphan Drug Designation for various cancer treatments.
